Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Former House Majority Leader Eric Cantor is stepping into one of Washington's hotmost seats — the presidency of PhRMA, the pharmaceutical industry's top lobbying group. Cantor, 63, takes over on Nov. 9, succeeding Steve Ubl after his 11-year tenure. The timing is notable: the pharma industry is under bipartisan fire over drug pricing, and a potential Democratic House takeover could intensify that scrutiny.
Former House Majority Leader Eric Cantor is heading to one of the most politically charged roles in healthcare — president and CEO of PhRMA, the powerful lobbying arm of the pharmaceutical industry. Cantor, who represented Virginia in Congress from 2000 to 2014 and later became a Wall Street executive at Moelis & Company, takes the helm on Nov. 9, succeeding Steve Ubl, who announced his departure in April after 11 years leading the organization.
The appointment comes at a turbulent moment for Big Pharma. Drug pricing remains a top voter concern, with polls showing overwhelming majorities of Americans view current prescription prices as unreasonable. If Democrats retake the House in November's midterms, they've signaled plans to dig into pharma companies' confidential pricing deals with the White House.
Key Takeaways:
Why it matters: With drug affordability dominating the political conversation, PhRMA's leadership choice signals the industry is bracing for a tough fight — and betting on a seasoned Washington insider to weather the storm.
